New research reveals that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end traditional lifestyle regimens.
Research printed in a major health publication shows that while obese individuals can lose substantial amounts of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying these medications should be informed of the danger of quick rebound weight gain when the medication ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain suggests a return to pre-treatment mass in about one and a half years.
Weighing Treatments
The research, which reviewed dozens of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with other pills.
The team emphasize that individuals who shed pounds through diet and exercise usually see a less rapid creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Quick Rebound
Doctors propose the mode of action of the drugs is key to understanding the accelerated rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of the hormone levels far above than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication means hunger is no longer kept in check, making binge eating a significant risk."
A Chronic Condition?
The NHS recommend the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, due to the significant potential of relapse, the therapy is often life-long.
This perspective is reinforced by drug manufacturers, who state that the findings "underscore the long-term character of obesity," comparing it to managing conditions like hypertension.
Patient Accounts
Individuals who have come off the jabs report a sudden return of hunger.
"It was like something flipping and you're instantly extremely hungry," described an individual.
This challenge is worsened if users have not established permanent dietary or behavioural changes during treatment.
Significant Adoption
Figures suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is more common among women than males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while these medications are powerful tools for weight loss, they are not a standalone fix and long-term success likely depends on integrated behavioural support.
